Jump to content

Chemo Combo Promising for Lung Cancer


Recommended Posts

Chemo Combo Promising for Lung Cancer

(Ivanhoe Newswire) -- A combination of two chemotherapy regimens may be a viable alternative to current treatments for non-small cell lung cancer.

A study conducted at Kinki University School of Medicine in Osaka, Japan, looked at how effective two different chemotherapy agents were in treating lung cancer. Currently the agents are most often used in treating gastric and colorectal cancers. One agent known as S-1 showed a response rate of 22 percent with a median survival time of 10.2 months when tested as a first-line chemotherapy for advanced lung cancer.

When the S-1 treatment was used in combination with Irinotecan, which is approved in the U.S. for treating colon cancer, the response rate was 28 percent. Median progression-free survival was 4.9 months and the median overall survival was 15 months.

The study’s lead investigator, Isamu Okamoto, M.D., Ph.D. an associate professor of oncology, said the findings “compared favorably” with the standard platinum-based lung cancer treatments, which show response rates of 17 to 33 percent, progression-free survival of three to five months and a median overall survival time of seven to 14 months. “This is a promising alternative but needs further testing in randomized trials,” Okamoto was quoted as saying.

SOURCE: Clinical Cancer Research, August 15, 2008

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.